醒脑静注射液联合吡拉西坦治疗急性脑梗死的临床疗效

摘要

目的 观察醒脑静注射液联合吡拉西坦治疗急性脑梗死的临床效果.方法 急性脑梗死患者90例,随机均分为两组,分别采用吡拉西坦治疗(对照组)和醒脑静联合吡拉西坦治疗(试验组).治疗方法:吡拉西坦100 ml,静脉输注,每天2次;醒脑静注射液20 ml,加入生理盐水250 ml,静脉输注,每天1次;10 d为1个疗程.比较两组疗效.结果 两组患者治疗后的神经缺损评分均较治疗前降低(P<0.05),试验组的改善程度优于对照组[(13.88±5.33)分v s.(20.85±6.13)分](P<0.05).治疗1个疗程后,试验组总有效率和显效率优于对照组(91.11%v s.66.67%和68.89%v s.48.89%)(P<0.05).结论 醒脑静注射液联合吡拉西坦较单用吡拉西坦治疗急性脑梗死患者更能有效改善神经功能.%Objective To observe the clinical efficacy of Xingnaojing injection combined with piracetam in treating acute cerebral infarction (ACI) .Methods Ninety patients with ACI were equally randomized into two groups .The patients in group P were treated with intravenous infusion of piracetam 100 ml ,twice a day for 10 days .The patients in group XP were given additional infusion of Xingnaojing injection 20 ml in normal saline 250 ml ,daily for 10 days .Clinical efficacy was compared between two groups .Results The neurologic deficit score of two groups was significantly lower after treatment than that before(P<0 .05) ,which after treatment was lower in group XP than that in group P[(13.88 ± 5.33 ) points vs .(20.85 ± 6.13 ) points ] ( P<0 .05 ) .After treatment ,the overall effectiveness rate and excellent rate were higher in group XP than those in group P (91.11% vs . 66.67% and 68.89% vs .48.89% )(P<0 .05) .Conclusion Clinical efficacy of Xingnaojing injection combined with piracetam is better than piracetam alone in improving neurological function in the patients with ACI .